Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Gareth Pryce"'
Publikováno v:
Pharmaceuticals, Vol 16, Iss 7, p 972 (2023)
Big conductance calcium-activated (BK) channel openers can inhibit pathologically driven neural hyperactivity to control symptoms via hyperpolarizing signals to limit neural excitability. We hypothesized that BK channel openers would be neuroprotecti
Externí odkaz:
https://doaj.org/article/a0bc6b4340914182a86b60587a142640
Autor:
David Baker, Liaqat Ali, Gauri Saxena, Gareth Pryce, Meleri Jones, Klaus Schmierer, Gavin Giovannoni, Sharmilee Gnanapavan, Kathleen C. Munger, Lawrence Samkoff, Andrew Goodman, Angray S. Kang
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Alemtuzumab was designed to reduce the immunogenicity of the parent CD52-specific rat immunoglobulin. Although originally marketed for use in cancer (Mabcampath®), alemtuzumab is currently licensed and formulated for the treatment of relapsing multi
Externí odkaz:
https://doaj.org/article/628cfa68c52f4ac0a00b5bff39da13e7
Publikováno v:
EBioMedicine, Vol 16, Iss C, Pp 41-50 (2017)
Although multiple sclerosis (MS) is considered to be a CD4, Th17-mediated autoimmune disease, supportive evidence is perhaps circumstantial, often based on animal studies, and is questioned by the perceived failure of CD4-depleting antibodies to cont
Externí odkaz:
https://doaj.org/article/3e66d26fae384b4e9764d3626a848f48
Publikováno v:
PLoS ONE, Vol 11, Iss 6, p e0157754 (2016)
Multiple sclerosis (MS) is a debilitating immune-mediated neurological disorder affecting young adults. MS is primarily relapsing-remitting, but neurodegeneration and disability accumulate from disease onset. The most commonly used mouse MS models ex
Externí odkaz:
https://doaj.org/article/cdbd215cf02a460ea7828eb7f991ce93
Autor:
Sofia Sisay, Gareth Pryce, Samuel J Jackson, Carolyn Tanner, Ruth A Ross, Gregory J Michael, David L Selwood, Gavin Giovannoni, David Baker
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e76907 (2013)
Endocannabinoids and some phytocannabinoids bind to CB1 and CB2 cannabinoid receptors, transient receptor potential vanilloid one (TRPV1) receptor and the orphan G protein receptor fifty-five (GPR55). Studies using C57BL/10 and C57BL/6 (Cnr2 (tm1Zim)
Externí odkaz:
https://doaj.org/article/0d32f5bcecba45b6acecca178110bd73
Publikováno v:
Pharmaceuticals; Volume 16; Issue 7; Pages: 972
Big conductance calcium-activated (BK) channel openers can inhibit pathologically driven neural hyperactivity to control symptoms via hyperpolarizing signals to limit neural excitability. We hypothesized that BK channel openers would be neuroprotecti
Publikováno v:
European Journal of Neurology. 27:221-228
Clinical trials are probably the most informative experiments to help an understanding of multiple sclerosis (MS) biology. Recent successes with CD20-depleting antibodies have focused attention towards B cell subsets as important mediators in MS. The
Autor:
Graham R. Campbell, Arpan R Metha, Yolanda S. Kap, Daniel Altman, Chao Zhao, David Baker, Stephen M. Anderton, Siddharthan Chandran, Katie McGill, Kenneth Smith, Bruce D. Trapp, Hans Lassmann, Jon D. Laman, Bert A t'Hart, Moses Rodriguez, Don J. Mahad, Stephanie E J Zandee, Robin J.M. Franklin, Sarah Al-Azki, Simon Licht-Mayer, Markus Kipp, Alex Symonds, Gareth Pryce
Axon loss is a cardinal neuropathological feature of multiple sclerosis (MS). Axonal injury in MS and experimental disease models is most frequently detected in acutely demyelinating regions. Furthermore, acute axonal injury consistently correlates w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d200d032d9cb001e6fcf387053783b5
https://doi.org/10.1101/2021.09.27.461926
https://doi.org/10.1101/2021.09.27.461926
Autor:
Sharmilee Gnanapavan, David Baker, Monica Marta, Paul I. Creeke, Gavin Giovannoni, Gareth Pryce
Publikováno v:
Multiple sclerosis and related disorders. 56
Background: Antigen-specific tolerance in auto-immune diseases is the goal for effective treatment with minimal side-effects. Whilst this is achievable in animal models, notably via intravenous delivery of the model-specific autoantigen following tra
Publikováno v:
Multiple Sclerosis and Related Disorders. 30:176-186
Oral cladribine is a novel treatment for relapsing multiple sclerosis (MS). This appears to be a semi-selective immune-reconstitution therapy that induces long-term therapy from short treatment cycles. It has a relatively good safety profile that cur